Sage Therapeutic Valuation
| SAGE Stock | USD 9.11 0.03 0.33% |
At this time, the company appears to be overvalued. Sage Therapeutic has a current Real Value of $8.35 per share. The regular price of the company is $9.11. Our model measures the value of Sage Therapeutic from inspecting the company fundamentals such as Shares Owned By Insiders of 10.40 %, return on equity of -0.64, and Current Valuation of 158.49 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sage Therapeutic's price fluctuation is slightly risky at this time. Calculation of the real value of Sage Therapeutic is based on 3 months time horizon. Increasing Sage Therapeutic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sage stock is determined by what a typical buyer is willing to pay for full or partial control of Sage Therapeutic. Since Sage Therapeutic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sage Stock. However, Sage Therapeutic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.11 | Real 8.35 | Hype 9.16 | Naive 8.79 |
The real value of Sage Stock, also known as its intrinsic value, is the underlying worth of Sage Therapeutic Company, which is reflected in its stock price. It is based on Sage Therapeutic's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sage Therapeutic's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sage Therapeutic helps investors to forecast how Sage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sage Therapeutic more accurately as focusing exclusively on Sage Therapeutic's fundamentals will not take into account other important factors: Sage Therapeutic Total Value Analysis
Sage Therapeutic is at this time forecasted to have valuation of 158.49 M with market capitalization of 570.49 M, debt of 11.84 M, and cash on hands of 1.51 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Sage Therapeutic fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
158.49 M | 570.49 M | 11.84 M | 1.51 B |
Sage Therapeutic Investor Information
About 84.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.39. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sage Therapeutic has Price/Earnings To Growth (PEG) ratio of 0.74. The entity recorded a loss per share of 5.8. The firm had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Sage Therapeutic's historical financial statements, Sage Therapeutic is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Sage Therapeutic Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sage Therapeutic has an asset utilization ratio of 7.54 percent. This indicates that the Company is making $0.0754 for each dollar of assets. An increasing asset utilization means that Sage Therapeutic is more efficient with each dollar of assets it utilizes for everyday operations.Sage Therapeutic Ownership Allocation
Sage Therapeutic shows a total of 62.62 Million outstanding shares. The majority of Sage Therapeutic outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sage Therapeutic to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sage Therapeutic. Please pay attention to any change in the institutional holdings of Sage Therapeutic as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sage Therapeutic Profitability Analysis
The company reported the previous year's revenue of 41.24 M. Net Loss for the year was (400.67 M) with loss before overhead, payroll, taxes, and interest of (138.35 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Sage Therapeutic's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Sage Therapeutic and how it compares across the competition.
About Sage Therapeutic Valuation
The stock valuation mechanism determines Sage Therapeutic's current worth on a weekly basis. Our valuation model uses a comparative analysis of Sage Therapeutic. We calculate exposure to Sage Therapeutic's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sage Therapeutic's related companies.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Sage Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 471 people.
Sage Therapeutic Growth Indicators
Investing in growth stocks can be very risky. If the company such as Sage Therapeutic does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 60.8 M |
Complementary Tools for Sage Stock analysis
When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |